Study summary · research use only
New directions in growth hormone treatment in children
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review (paediatric human patients) discusses clinical-trial evidence on long-acting growth hormone (LAGH) preparations in children. Three LAGH products — lonapegsomatropin, somapacitan, and somatrogon — are noted as approved in Europe and the United States for paediatric growth hormone deficiency. The review describes ongoing trial programmes evaluating these agents in Turner syndrome, Noonan syndrome, children born small for gestational age/intrauterine growth restriction, idiopathic short stature, SHOX gene variants, and achondroplasia, and summarizes trial design assumptions. It also discusses potential use of LAGH in adults transitioning from paediatric GHD who require ongoing replacement therapy. Preliminary data are presented on an oral growth hormone secretagogue, ibutamoren, in children with partial GH deficiency.
Abstract
This paper reviews clinical-trial evidence on the use of long-acting growth hormone (LAGH) preparations in children. Three LAGH products have been approved in Europe and the United States for paediatric growth hormone deficiency (GHD): lonapegsomatropin, somapacitan, and somatrogon. Ongoing clinical programmes are evaluating these agents in other causes of short stature that may warrant growth hormone therapy, including Turner syndrome, Noonan syndrome, children born small for gestational age (SGA)/with intrauterine growth restriction (IUGR), idiopathic short stature (ISS), SHOX gene variants, and achondroplasia; the present article summarises the design assumptions of these trials. In addition, the paper discusses the potential role of LAGH in patients with persistent GHD after completion of linear growth, i.e. those transitioning into adulthood and requiring ongoing replacement therapy. Finally, preliminary data are presented on the use of an oral growth hormone secretagogue, ibutamoren, in children with partial GH deficiency.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.